// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

Impact of obesity on rheumatoid arthritis (RA onset and progression. in vivo and in vitro effects of synthetic dmards on the ra-associated metabolic alterations

I. Arias De La Rosa - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Positive remodelling index and low attenuation non-calcified coronary plaques: markers of vulnerable coronary plaques in systemic lupus?

G. Stojan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Dyslipidemia

Hydroxychloroquine

Predictors of drug-free remission in rheumatoid arthritis: results from the prospective biomarkers of remission in rheumatoid arthritis(BIORRA study

K.F. Baker - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

A Case of Aleukemic Leukemia Cutis Mistaken for Sarcoidosis

Diana V. Rodríguez-Rivera - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Acute myelocytic leukemia

Hydroxychloroquine

Scleroderma associated with immune checkpoint inhibitor durvalumab

Alexandria Brown - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lung Cancer

Hydroxychloroquine

Verrucous Sarcoidosis: A rare variant of cutaneous sarcoidosis

Abigale Clark - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sarcoidosis

Hydroxychloroquine

Two cases of oral baricitinib associated papular eruption on face

Joo Yeon Ko - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Update on systemic treatment options for generalized granuloma annulare

Matthew L. Hrin - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Treatment patterns for hydroxychloroquine, methotrexate, and mycophenolate mofetil in lichen planopilaris

Josiah Williams - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Treatment with rituximab for refractory adult dermatomyositis complicated with calcinosis cutis

Sophia Ly - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Juvenile dermatomyositis

Hydroxychloroquine

Diffuse Annular Elastolytic Giant Cell Granuloma with a Rapid Response to Hydroxychloroquine

Morgan McNeil - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Monoclonal gammopathy

Hydroxychloroquine

Lupus Panniculitis with Facial Hemiatrophy

Ashlee Margheim - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Angina

Hydroxychloroquine

A Remarkably Spongy Scalp in a Patient with Hair Loss: Lichen Planopilaris Occurring Simultaneously with Lipedematous Scalp

Erin Garfield - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

A case of systemic lupus erythematous presenting with macrophage activation syndrome

Cody J. Rasner - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Macrophage activation syndrome

Hydroxychloroquine

Diagnosing a rare but life-threatening disease: Catastrophic Antiphospholipid Syndrome

Moarij Qazi - National Kidney Foundation (NKF) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Antiphospholipid syndrome

Hydroxychloroquine

SARS-CoV-2 spike binding peptides: A potential therapeutic approach for COVID-19

Santhamani Ramasamy - American Association of Immunologists (AAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Hydroxychloroquine

Assessing the Association Between Hydroxychloroquine and Preeclampsia Risk in SLE Pregnancies Using Administrative Claims Data

Amadeia Rector - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis

Alba Herrero-Morant - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry

Chiharu Hidekawa - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use

Anna Broder - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Microvascular complications of diabetes 1

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved